GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022
April 11, 2022 07:30 ET
|
GT Biopharma, Inc.
- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3 TriKE efficacy in the HNSCC tumor...
GT Biopharma Announces Closing of Private Placement Financing and Provides Business Update
February 06, 2019 16:01 ET
|
GT Biopharma, Inc.
Corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 Company on track to report topline Phase 2a data of GTB-1550 this quarter ...
GT Biopharma, Inc. to Present at Biotech Showcase™ 2019
December 20, 2018 08:22 ET
|
GT Biopharma, Inc.
– Presentation with live audio webcast, Tuesday, January 8, 2019 at 11:30 AM PST – LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT...
GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
December 06, 2018 08:05 ET
|
GT Biopharma, Inc.
– Company’s proprietary TriKE product candidates have the potential to serve as a relatively safe, cost-effective, and easy-to-use therapy for refractory/relapsed AML, high-risk MDS and advanced...
GT Biopharma Announces Presentation of Two Abstracts at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition
November 20, 2018 07:30 ET
|
GT Biopharma, Inc.
LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on...
GT Biopharma Reports Third Quarter 2018 Financial Results and Provides Business Update
November 15, 2018 08:00 ET
|
GT Biopharma, Inc.
– Recent corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 – – FDA clearance of IND to advance first-in-class TriKE, GTB-3550, into...
GT Biopharma Receives FDA Clearance to Commence First-in-Human Phase 1 Study of its First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550, for the Treatment of Acute Myelogenous Leukemia, Myelodysplatic Syndrome and Mastocytosis
November 01, 2018 09:30 ET
|
GT Biopharma, Inc.
LOS ANGELES, Nov. 01, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on...
GT Biopharma, Inc. Files Application for NASDAQ Capital Market Listing
December 18, 2017 10:47 ET
|
GT Biopharma, Inc.
WASHINGTON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- GT Biopharma Inc. (OTCQB:GTBP) today announced that the Company has filed an application to list its common stock on the NASDAQ Capital Market. GT...